Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezampanel for Opioid Withdrawal Syndrome in OUD
NCT06538558Phase 1Recruiting
- Sponsor
- Proniras Corporation
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of tezampanel in opioid withdrawal syndrome (OWS) (4 cohorts), sponsored by Proniras Corporation. Primary endpoint: Systemic tolerability and safety of intravenous tezampanel administration at Day 10. Started Oct 2024; status: recruiting.
02
Drugs
tezampanel
03
Conditions
opioid withdrawal syndrome (OWS)
Beyond the preview
Go deeper on NCT06538558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538558.